CoreWeave, Inc. filings document the regulatory record for an AI cloud infrastructure company listed on Nasdaq with Class A common stock. The company’s 8-K reports cover operating results, customer cloud-capacity agreements, private placements of equity securities, senior notes, credit facilities, and related guarantees or collateral arrangements.
Proxy materials disclose annual meeting matters, stockholder voting items, board governance, executive compensation, and equity-award information. Capital-structure filings describe senior unsecured notes due 2031, subsidiary guarantees, private placement registration rights, and debt facilities used to finance GPU servers and related infrastructure for customer contracts.
CRWV has a notice to sell 281,250 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of 26,780,625.00. These shares are part of a class with 386,401,201 shares outstanding and are expected to be sold on or around 01/21/2026 on the NASDAQ.
The shares to be sold were acquired as founders shares from the issuer on 12/27/2023, in a single block of 281,250 shares. Over the past three months, related parties such as West Clay Capital LLC, Brian Venturo, YOLO APV Trust, YOLO ECV Trust, and a non-affiliate donee have already sold multiple blocks of CRWV common stock, each transaction generating multi-million dollar gross proceeds under Rule 10b5-1 trading arrangements.
A shareholder has filed a Rule 144 notice to sell common stock. The filing covers the planned sale of 8,335 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of 843,752.05, and notes 386,401,201 shares outstanding and an approximate sale date of 01/20/2026 on NASDAQ.
The shares to be sold are founders’ common shares acquired from the issuer on 02/25/2019. The filing also lists extensive recent sales of common stock over the prior three months by Brannin J. McBee, related trusts and entities using 10b5-1 trading arrangements, and a non‑affiliate donee, including a 257,733‑share sale by a non‑affiliate donee for 19,592,527.61.
By signing, the selling person represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations, consistent with Rule 144 and Rule 10b5-1 requirements.
A holder of CRWV common stock filed a Form 144 notice to sell 25,000 shares through Morgan Stanley Smith Barney on the NASDAQ, with an aggregate market value of 2,530,750.00. The issuer reports 386,401,201 common shares outstanding, showing the planned sale is small relative to the total base.
The shares to be sold are common stock originally acquired as founders shares from the issuer on 02/25/2019. The filing also lists extensive Rule 10b5-1 sales over the past three months by Brannin McBee and related trusts, plus a non-affiliate donee, including individual transactions such as 102,835 shares sold on 01/12/2026 for 9,129,557.61 and 257,733 shares sold on 12/01/2025 for 19,592,527.61.
A shareholder of CRWV has filed a Form 144 notice to sell 1,000 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $101,230.00. The shares are part of a much larger base of 386,401,201 common shares outstanding and were originally acquired on 02/25/2019 as founder shares.
The planned sale is expected around 01/20/2026 on the NASDAQ. The filing also details extensive recent selling activity over the past three months under Rule 10b5-1 plans by Brannin McBee, several Canis Major and Canis Minor family and GRAT trusts, and a non-affiliate donee, involving multiple blocks of CRWV common stock with multi-million dollar gross proceeds.
A Form 144 notice reports a planned sale of 1,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated aggregate market value of 101230.00. The issuer has 386,401,201 common shares outstanding, and the shares to be sold were acquired as founders shares on 02/25/2019 from the issuer.
The filing also lists prior sales over the past three months by various related sellers, primarily under Rule 10b5-1 trading plans. These include multiple common stock sales on dates in December 2025 and January 2026 by several trusts and entities at the same Livingston, NJ address, as well as a Non-Affiliate Donee sale of 257,733 shares on 12/01/2025 for gross proceeds of 19592527.61.
A holder of CRWV common stock has filed a notice of proposed sale under Rule 144. The filing covers the planned sale of 3,000 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $303,690.00, against 386,401,201 common shares outstanding. The approximate sale date is listed as 01/20/2026 on the NASDAQ market.
The shares to be sold were acquired as founders shares from the issuer on 02/25/2019, in a transaction labeled as involving 3,000 common shares. The filing also lists extensive Rule 10b5-1 sales over the prior three months by Brannin McBee, related trusts and entities, and a non-affiliate donee, including individual transactions such as 102,835 common shares sold on 01/12/2026 for $9,129,557.61 and 25,000 common shares sold on 12/29/2025 for $1,890,665.00.
CRWV insider Brannin McBee filed a Form 144 notice covering a proposed sale of 102,835 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ around 01/20/2026, with an aggregate market value of $10,409,987.05. The filing notes 386,401,201 shares of common stock outstanding.
The 102,835 shares were originally acquired as founder shares from the issuer on 02/25/2019. The notice also lists extensive Rule 10b5‑1 sales of CRWV common stock during the past three months by Brannin McBee and multiple related trusts and entities, each showing specific dates, share amounts and gross proceeds.
CRWV stockholders filed a notice under Rule 144 to permit the sale of 500 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $50,615.00. The filing notes that these shares are part of 386,401,201 common shares outstanding and that the planned sale date is around 01/20/2026 on the NASDAQ market.
The seller acquired the 500 shares on 02/25/2019 as founders shares from the issuer. The document also lists extensive Rule 10b5‑1 sales of CRWV common stock over the prior three months by various trusts and entities at the same address, including multiple block trades such as 25,000‑share transactions and a 257,733‑share sale by a non‑affiliate donee.
CoreWeave CEO, President and director Michael N. Intrator, a more than 10% owner, reported multiple transactions in the company’s Class A and Class B common stock on January 14, 2026 under a pre‑arranged Rule 10b5‑1 trading plan adopted on May 23, 2025.
He completed several open‑market sales of Class A common stock at weighted average prices ranging from about $87.43 to $93.15 per share, and held 5,828,779 Class A shares directly afterward. Through Omnadora Capital LLC, a related entity he may be deemed to beneficially own, 50,000 Class B shares converted into 50,000 Class A shares, which were then sold in multiple tranches at similar prices, leaving no Class A shares at Omnadora and 25,099,280 Class B shares indirectly held through it.
Intrator also reports additional Class B common stock indirectly held via family trusts and his spouse, including 21,867,489 Class B shares held directly in his name and sizable positions in several named trusts. Each Class B share is convertible into one Class A share under the company’s charter.
CoreWeave, Inc.’s Chief Development Officer McBee Brannin reported indirect transactions involving family-related entities in the company’s Class A and Class B common stock on January 12, 2026. The Canis Minor 2025 GRAT converted 8,335 shares of Class B common stock into Class A common stock and then sold those Class A shares in multiple trades under a Rule 10b5-1 trading plan at weighted average prices noted in the filing.
Additional small sales of Class A common stock were reported by the Canis Major SM Trust, with each sale disclosed at its own weighted average price. Following these transactions, indirect holdings reported include Class B common stock and corresponding convertible Class A interests held through the Canis Minor 2025 GRAT, Class B common stock held by Brannin’s spouse, and Class A common stock held by the Canis Major SM Trust and by Brannin’s child.